Additional information
Notes on contributors
Mark Wagner
Mark Wagner, PharmD, completed his PGY2 oncology pharmacy practice residency at St. Luke's MSTI in 2016 and is practicing as a clinical oncology pharmacist at the Cowell Family Cancer Center. Jessie Modlin, PharmD, is research pharmacist; Jennifer Eichmeyer, MS, CGC, is lead genetic counselor; and Jessica Monitz, PharmD, completed her PGY1 pharmacy practice residency at St. Luke's Medical Center. Paul Montgomery, MD, is the medical director of MSTI Research and one of three principal investigators of the newly formed Pacific Cancer Research Consortium that includes Providence Portland Medical Center, Swedish Cancer Institute; and Mountain States Tumor Institute. Natalie Perry is research project coordinator at MSTI.
Jennifer Eichmeyer
Mark Wagner, PharmD, completed his PGY2 oncology pharmacy practice residency at St. Luke's MSTI in 2016 and is practicing as a clinical oncology pharmacist at the Cowell Family Cancer Center. Jessie Modlin, PharmD, is research pharmacist; Jennifer Eichmeyer, MS, CGC, is lead genetic counselor; and Jessica Monitz, PharmD, completed her PGY1 pharmacy practice residency at St. Luke's Medical Center. Paul Montgomery, MD, is the medical director of MSTI Research and one of three principal investigators of the newly formed Pacific Cancer Research Consortium that includes Providence Portland Medical Center, Swedish Cancer Institute; and Mountain States Tumor Institute. Natalie Perry is research project coordinator at MSTI.
Paul G. Montgomery
Mark Wagner, PharmD, completed his PGY2 oncology pharmacy practice residency at St. Luke's MSTI in 2016 and is practicing as a clinical oncology pharmacist at the Cowell Family Cancer Center. Jessie Modlin, PharmD, is research pharmacist; Jennifer Eichmeyer, MS, CGC, is lead genetic counselor; and Jessica Monitz, PharmD, completed her PGY1 pharmacy practice residency at St. Luke's Medical Center. Paul Montgomery, MD, is the medical director of MSTI Research and one of three principal investigators of the newly formed Pacific Cancer Research Consortium that includes Providence Portland Medical Center, Swedish Cancer Institute; and Mountain States Tumor Institute. Natalie Perry is research project coordinator at MSTI.
Jessica Monitz
Mark Wagner, PharmD, completed his PGY2 oncology pharmacy practice residency at St. Luke's MSTI in 2016 and is practicing as a clinical oncology pharmacist at the Cowell Family Cancer Center. Jessie Modlin, PharmD, is research pharmacist; Jennifer Eichmeyer, MS, CGC, is lead genetic counselor; and Jessica Monitz, PharmD, completed her PGY1 pharmacy practice residency at St. Luke's Medical Center. Paul Montgomery, MD, is the medical director of MSTI Research and one of three principal investigators of the newly formed Pacific Cancer Research Consortium that includes Providence Portland Medical Center, Swedish Cancer Institute; and Mountain States Tumor Institute. Natalie Perry is research project coordinator at MSTI.
Jessie Modlin
Mark Wagner, PharmD, completed his PGY2 oncology pharmacy practice residency at St. Luke's MSTI in 2016 and is practicing as a clinical oncology pharmacist at the Cowell Family Cancer Center. Jessie Modlin, PharmD, is research pharmacist; Jennifer Eichmeyer, MS, CGC, is lead genetic counselor; and Jessica Monitz, PharmD, completed her PGY1 pharmacy practice residency at St. Luke's Medical Center. Paul Montgomery, MD, is the medical director of MSTI Research and one of three principal investigators of the newly formed Pacific Cancer Research Consortium that includes Providence Portland Medical Center, Swedish Cancer Institute; and Mountain States Tumor Institute. Natalie Perry is research project coordinator at MSTI.
Natalie Perry
Mark Wagner, PharmD, completed his PGY2 oncology pharmacy practice residency at St. Luke's MSTI in 2016 and is practicing as a clinical oncology pharmacist at the Cowell Family Cancer Center. Jessie Modlin, PharmD, is research pharmacist; Jennifer Eichmeyer, MS, CGC, is lead genetic counselor; and Jessica Monitz, PharmD, completed her PGY1 pharmacy practice residency at St. Luke's Medical Center. Paul Montgomery, MD, is the medical director of MSTI Research and one of three principal investigators of the newly formed Pacific Cancer Research Consortium that includes Providence Portland Medical Center, Swedish Cancer Institute; and Mountain States Tumor Institute. Natalie Perry is research project coordinator at MSTI.